Mixed
Accelerated brain aging, specifically measured by a cognition-optimized plasma proteomic model (CognitionBrain), predicts Alzheimer's disease progression and cognitive decline independently of and as strongly as the current best blood biomarker, pTau-181.
For those concerned about Alzheimer's, this research suggests that a new blood test measuring brain-specific aging (CognitionBrain) is just as powerful as the current gold standard (pTau-181) and provides additional, independent information. Using both together offers the best prediction of cognitive decline. This highlights the importance of early, multi-faceted biomarker screening for those with family history or risk factors, rather than relying on a single test.
accelerated brain and vascular aging predict Alzheimer’s disease (AD) progression independently from and as strongly as plasma pTau-181 (ref. 5), the current best blood-based biomarker for AD.
Why this rating
Replicated across multiple cohorts, independent of pTau-181, and additive for risk prediction.
Source
Organ aging signatures in the plasma proteome track health and disease
Hamilton Oh et al. · Nature · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →